HBV-associated cryoglobulinemic vasculitis: remission after antiviral therapy with entecavir

Kidney Blood Press Res. 2014;39(1):65-73. doi: 10.1159/000355778. Epub 2014 Jun 23.

Abstract

Background/aims: Cryoglobulinemic vasculitis remains an uncommon complication of hepatitis B virus infection.

Methods: We report the case of a 40-years old female Chinese patient with chronic hepatitis B developing cryoglobulinemic vasculitis with multiple organ involvement (liver, kidney, and skin) coupled with weakness, arthralgias, haemolytic anaemia, and autoimmune thyroiditis. She received entecavir mono-therapy at dose adjusted for estimated glomerular filtration rate.

Results: Within five months of entecavir treatment, hepatitis B viraemia decreased below the limit of detection with normal serum amino-transferase levels, HBeAg clearance occurred, vasculitis regressed with disappearance of purpura and ascites; in addition, renal function normalized and nephritic syndrome remitted. After a five-year follow-up, the patient is asymptomatic with intact kidney function, proteinuria in the normal range, and normal liver biochemistry, despite the antiviral treatment was withdrawn and the patient remained HBsAg positive.

Conclusions: This is the second case of hepatitis B virus-related cryoglobulinemic vasculitis successfully treated with entecavir suggesting that effective antiviral therapy may counteract both the hepatic and extra-hepatic manifestations of infection by hepatitis B virus.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use*
  • Comorbidity
  • Cryoglobulinemia / drug therapy*
  • Cryoglobulinemia / etiology*
  • Dose-Response Relationship, Drug
  • Female
  • Follow-Up Studies
  • Guanine / analogs & derivatives*
  • Guanine / therapeutic use
  • Hepatitis B Surface Antigens / blood
  • Hepatitis B virus
  • Hepatitis B, Chronic / complications*
  • Hepatitis B, Chronic / drug therapy
  • Humans
  • Remission Induction
  • Transaminases / blood
  • Treatment Outcome
  • Vasculitis / drug therapy*
  • Vasculitis / etiology*

Substances

  • Antiviral Agents
  • Hepatitis B Surface Antigens
  • entecavir
  • Guanine
  • Transaminases